Stemline Therapeutics to Present at Upcoming Investor Conferences
September 20, 2017
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE)
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D., Stemline’s CEO, will be presenting at two upcoming investor conferences.
